Orion Portfolio Solutions LLC Takes Position in Sanofi SA (NYSE:SNY)
Orion Portfolio Solutions LLC bought a new stake in Sanofi SA (NYSE:SNY) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 2,126 shares of the company’s stock, valued at approximately $107,000.
Other hedge funds have also modified their holdings of the company. FMR LLC increased its stake in Sanofi by 32.4% during the 4th quarter. FMR LLC now owns 10,590,253 shares of the company’s stock worth $531,630,000 after buying an additional 2,593,620 shares during the period. Bank of America Corp DE increased its stake in Sanofi by 28.2% during the 4th quarter. Bank of America Corp DE now owns 7,316,201 shares of the company’s stock worth $367,274,000 after buying an additional 1,607,859 shares during the period. Hotchkis & Wiley Capital Management LLC increased its stake in Sanofi by 10.8% during the 4th quarter. Hotchkis & Wiley Capital Management LLC now owns 3,450,887 shares of the company’s stock worth $173,235,000 after buying an additional 337,755 shares during the period. Parametric Portfolio Associates LLC increased its stake in Sanofi by 2.9% during the 3rd quarter. Parametric Portfolio Associates LLC now owns 2,103,412 shares of the company’s stock worth $97,451,000 after buying an additional 59,672 shares during the period. Finally, Artisan Partners Limited Partnership increased its stake in Sanofi by 7.9% during the 4th quarter. Artisan Partners Limited Partnership now owns 1,534,819 shares of the company’s stock worth $77,048,000 after buying an additional 112,996 shares during the period. 7.04% of the stock is currently owned by institutional investors and hedge funds.
Shares of NYSE SNY traded up $1.18 during midday trading on Wednesday, hitting $41.37. The company’s stock had a trading volume of 5,104,607 shares, compared to its average volume of 2,334,279. The company has a debt-to-equity ratio of 0.40, a quick ratio of 0.85 and a current ratio of 1.22. The firm’s fifty day moving average price is $47.13 and its 200-day moving average price is $47.31. The firm has a market cap of $101.49 billion, a P/E ratio of 13.22, a P/E/G ratio of 2.41 and a beta of 0.67. Sanofi SA has a 1-year low of $37.62 and a 1-year high of $51.84.
Several equities research analysts have recently weighed in on the stock. JPMorgan Chase & Co. raised shares of Sanofi from a “neutral” rating to an “overweight” rating in a research report on Sunday, January 5th. They noted that the move was a valuation call. Goldman Sachs Group raised shares of Sanofi from a “neutral” rating to a “buy” rating in a research report on Tuesday, March 10th. DZ Bank reaffirmed a “neutral” rating on shares of Sanofi in a report on Friday, February 7th. Barclays raised shares of Sanofi from an “underweight” rating to an “equal weight” rating in a report on Tuesday, March 17th. Finally, SVB Leerink began coverage on shares of Sanofi in a report on Tuesday, February 11th. They issued a “market perform” rating and a $58.00 price target for the company. Five investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Sanofi currently has a consensus rating of “Buy” and an average target price of $55.00.
Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.
Read More: What is an economic bubble?
Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi SA (NYSE:SNY).
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.